| PFS | OS | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
ECOG PS | Â | Â | Â | Â | Â | Â |
  2/3 versus 0/1 (Ref) | 2.27 | 1.25–4.10 | 0.007 | - | - | - |
Primary site | Â | Â | Â | Â | Â | Â |
  GEJ versus Stomach (Ref) | - | - | - | - | - | - |
Weight loss | Â | Â | Â | Â | Â | Â |
  Yes versus No (Ref) | 1.67 | 1.21–2.28 | 0.001 | 1.46 | 1.04–2.01 | 0.030 |
Peritoneal seeding | Â | Â | Â | Â | Â | Â |
  Yes versus No (Ref) | - | - | - | 1.76 | 1.10–2.80 | 0.019 |
MSI/MMR status | Â | Â | Â | Â | Â | Â |
  MSI-H/dMMR versus others (Ref) | 0.23 | 0.10–0.53 | 0.001 | 0.03 | 0.004–0.21 | < 0.001 |
Serum sodium, mEq/L | Â | Â | Â | Â | Â | Â |
  < 135 versus ≥ 135 (Ref) | - | - | - | 1.92 | 1.24–2.96 | 0.003 |
Serum albumin, g/dL | Â | Â | Â | Â | Â | Â |
  < 3.5 versus ≥ 3.5 (Ref) | - | - | - | 1.78 | 1.19–2.66 | 0.005 |
Duration of 2nd line therapya | Â | Â | Â | Â | Â | Â |
  <median versus ≥ median (Ref) | - | - | - | 2.17 | 1.53–3.08 | < 0.001 |